Hostname: page-component-848d4c4894-pftt2 Total loading time: 0 Render date: 2024-05-16T22:34:15.326Z Has data issue: false hasContentIssue false
  • English
  • Français

Creatine Kinase Elevations with Clozapine

Published online by Cambridge University Press:  02 January 2018

Matcheri S. Keshavan ,
John Stecker  and
R. Krishna Kambhampati
Matcheri S. Keshavan*
Affiliation:
Schizophrenia Inpatient Unit, University of Pittsburgh
John Stecker
Affiliation:
University of Pittsburgh, Western Psychiatric Institute and Clinic, 3811 O'Hara Street, Pittsburgh, PA 15213, USA
R. Krishna Kambhampati
Affiliation:
Denton Regional Center, Flow Campus, 1310 Scripture Street, Denton, TX 76201
*
∗Correspondence
Get access Rights & Permissions [Opens in a new window]

Abstract

We describe a patient with marked elevations of creatine kinase following institution of clozapine treatment. The enzyme levels promptly subsided with discontinuation of clozapine. The clinical features did not meet any of the published criteria for neuroleptic malignant syndrome.

Type
Brief Reports
Information
The British Journal of Psychiatry , Volume 164 , Issue 1 , January 1994 , pp. 118 - 120
Copyright
Copyright © The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adityanjee, (1991) The myth of elevated serum creatine phosphokinase level and neuroleptic malignant syndrome. British Journal of Psychiatry, 158, 706–707.Google Scholar
Dinan, T. G. (1987) Calcium activated potassium conductance: an alternative to the dopamine hypothesis of neuroleptic action? British Journal of Psychiatry, 151, 455–459.Google Scholar
Fogel, B. S. & Goldberg, R. J. (1985) Neuroleptic malignant syndrome (letter). New England Journal of Medicine, 313, 1292.Google Scholar
Harsch, H. H. (1987) Neuroleptic malignant syndrome: physiological and laboratory findings in a series of nine cases. Journal of Clinical Psychiatry, 48, 328–333.Google Scholar
Kaufmann, C. A. & Wyatt, R. J. (1989) Neuroleptic malignant syndrome. In Psychopharmacology: The Third Generation of Progress (ed. Meltzer, H. Y.). New York: Raven Press.Google Scholar
Lazarus, A., Mann, S. & Caroff, S. N. (1989) The Neuroleptic Malignant Syndrome and Related Conditions (eds A. Lazarus, S. Mann & S. N. Caroff). Washington, DC: American Psychiatric Press.Google Scholar
Meltzer, H. Y. (1976) Neuromuscular dysfunction in schizophrenia. Schizophrenia Bulletin, 2, 106–135.Google Scholar
Pearlman, C., Wheadon, D. & Epstein, S. (1988) Creatine kinase elevation after neuroleptic treatment. American Journal of Psychiatry, 145, 1018–1019.Google Scholar
Ravi, S. D., Broge, G. F. & Roach, F. L. (1982) Neuroleptics, laryngeal-pharyngeal dystonia and acute renal failure. Journal of Clinical Psychiatry, 43, 300.Google Scholar
Weiss, B., Prozialeck, W. C. & Wallace, T. L. (1982) Interactions of drugs with calmodulin. Biochemical Pharmacology, 31, 2217–2226.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.